Conditions: Pulmonary Disease, Chronic Obstructive
Keywords: long-acting beta2-receptor agonist Safety and tolerability pharmacodynamics pharmacokinetics long-acting muscarinic receptor antagonist COPD
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 51
Healthy volunteers: no

Brief summary:
The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of inhaled GSK573719 and GW64244 compared to placebo, in subjects with COPD.

Detailed description:
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of the combination of GSK573719 (500mcg) Inhalation Powder and GW642444 (25mcg) Inhalation Powder administered once-daily via a novel dry powder inhaler (Novel DPI) over 28 days in subjects with COPD

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: 500mcg/25mcg once daily intervention 2: Placebo once daily
Intervention descriptions: intervention 1: GSK573719/GW642444 intervention 2: Inactive, excipients only

Protocol document: